Inbiomotion, a spin-off of IRB Barcelona and ICREA, is a personalized medicine company created in 2011 based on research conducted at the IRB Barcelona Growth control and cancer metastasis laboratory, led by Roger Gomis.
Roger wanted to bring his research to cancer patients to improve their quality of life, so he combined his science and business training to create Inbiomotion with the aim of developing biomarkers to predict future bone metastases from biopsies of primary tumors.
The company has received support from the Ysios Capital venture capital fund and Fundació Vila Casas since 2012 and in 2016 closed its second round of funding, attracting €2.2 millions thanks to the majority stake taken by Caixa Capital Risc – investing through its Caixa Innvierte BioMed II fund – and Ysios Capital – through its Ysios BioFund.
I had the perfect background: training in science and business. This knowledge helped me understand how the system and technology transfer work. When I realized the research we were doing had potential for being applied to patients, I knew that if I wanted it to happen I would have to be the one to do it. To apply our model, the investement of resources was needed and this application would've been lost if I hadn't created Inbiomotion.
I've made a lot of decisions over the years but the most important was surely looking for partners I see eye-to-eye with and that would accompany me throughout the process of setting up the company. Right now, we have different types of people working at Inbiomotion, from someone supervising product development to a pathologist.
I think the best advice I've ever been given was from a friend who's a business expert: if you're going to go into business, do it for real. That led me to seek Venture Capital and launch rounds of funding to be able to move forward with the project.
In conceptual terms, we want to validate the clinical utility of our diagnostic kit. In business terms, we want to generate enough know-how, enough value, to allow Inbiomotion to be absorbed by a large company.
With that, we also want to prove that research done in the laboratory can be successfully taken to market and have a direct impact on patients' quality of life.